Uterine carcinosarcoma
disease diseaseOn this page
Also known as carcinosarcoma of the uterusmalignant mixed mesodermal (Mullerian) tumor of the uterusmalignant mixed mesodermal (Mullerian) tumour of the uterusmalignant mixed mesodermal (Müllerian) tumor of the uterusmalignant mixed mesodermal (Müllerian) tumour of the uterusuterine carcinosarcoma/uterine malignant mixed mullerian tumoruterine carcinosarcoma/uterine malignant mixed mullerian tumouruterine malignant mixed mesodermal (Mullerian) tumoruterine malignant mixed mesodermal (Mullerian) tumouruterine malignant mixed mesodermal (Müllerian) tumoruterine malignant mixed mesodermal (Müllerian) tumouruterus carcinosarcoma
Summary
Uterine carcinosarcoma (MONDO:0006485) is a disease and 24 clinical trials. Top therapeutic interventions include rucaparib, sorafenib, and temsirolimus. A subtype of uterine cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 24
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | uterine carcinosarcoma |
| Mondo ID | MONDO:0006485 |
| EFO | EFO:1000613 |
| MeSH | D012192 |
| DOID | DOID:6171 |
| NCIT | C42700 |
| SNOMED CT | 702369008 |
| UMLS | C0280630 |
| MedGen | 83678 |
| GARD | 0027758 |
| Anatomy (UBERON) | UBERON:0000995 |
| Is cancer (heuristic) | no |
Also known as: carcinosarcoma of the uterus · malignant mixed mesodermal (Mullerian) tumor of the uterus · malignant mixed mesodermal (Mullerian) tumour of the uterus · malignant mixed mesodermal (Müllerian) tumor of the uterus · malignant mixed mesodermal (Müllerian) tumour of the uterus · uterine carcinosarcoma · uterine carcinosarcoma/uterine malignant mixed mullerian tumor · uterine carcinosarcoma/uterine malignant mixed mullerian tumour · uterine malignant mixed mesodermal (Mullerian) tumor · uterine malignant mixed mesodermal (Mullerian) tumour · uterine malignant mixed mesodermal (Müllerian) tumor · uterine malignant mixed mesodermal (Müllerian) tumour · uterus carcinosarcoma
Data availability: 36 cell lines · 24 intOGen driver records.
Disease family
This is a subtype of uterine cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinosarcoma
Related subtypes (6): uterine adnexa cancer, placenta cancer, cervical cancer, uterine carcinoma, uterine corpus cancer, endometrial cancer
Subtypes (2): cervical carcinosarcoma, carcinosarcoma of the corpus uteri
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
3 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Status |
|---|---|
| Carboplatin | Approved (phase 3) |
| Ifosfamide | Approved (phase 3) |
| Paclitaxel | Approved (phase 3) |
12 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Atezolizumab | Phase 2 |
| Bevacizumab | Phase 2 |
| Cabozantinib | Phase 2 |
| Iniparib | Phase 2 |
| Ipilimumab | Phase 2 |
| Ixabepilone | Phase 2 |
| Lenvatinib | Phase 2 |
| Nivolumab | Phase 2 |
| Pembrolizumab | Phase 2 |
| Rucaparib | Phase 2 |
| Temsirolimus | Phase 2 |
| Thalidomide | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 24.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 17 |
| Not specified | 3 |
| PHASE1 | 2 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00954174 | PHASE3 | UNKNOWN | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer |
| NCT04802876 | PHASE2 | ACTIVE_NOT_RECRUITING | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors |
| NCT05147558 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma |
| NCT05619913 | PHASE2 | RECRUITING | EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma |
| NCT05902988 | PHASE1/PHASE2 | RECRUITING | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer |
| NCT00025506 | PHASE2 | COMPLETED | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus |
| NCT00075400 | PHASE2 | COMPLETED | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer |
| NCT00114218 | PHASE2 | COMPLETED | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer |
| NCT00238121 | PHASE2 | COMPLETED | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer |
| NCT00245102 | PHASE2 | COMPLETED | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma |
| NCT00390234 | PHASE2 | COMPLETED | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma |
| NCT00478426 | PHASE2 | COMPLETED | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer |
| NCT00659360 | PHASE2 | COMPLETED | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma |
| NCT00687687 | PHASE2 | COMPLETED | Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma |
| NCT01010126 | PHASE2 | COMPLETED | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
| NCT01061606 | PHASE2 | TERMINATED | Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus |
| NCT01168232 | PHASE2 | COMPLETED | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer |
| NCT01247571 | PHASE2 | COMPLETED | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer |
| NCT03694262 | PHASE2 | COMPLETED | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) |
| NCT03552471 | PHASE1 | COMPLETED | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| NCT05229601 | PHASE1 | TERMINATED | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors |
| NCT01367301 | Not specified | TERMINATED | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer |
| NCT01991808 | Not specified | COMPLETED | Suitability of DCE-MRI for Detection of Vascular Changes After VBT |
| NCT03902379 | Not specified | WITHDRAWN | Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RUCAPARIB | 4 | 2 |
| SORAFENIB | 4 | 2 |
| TEMSIROLIMUS | 4 | 2 |
| ERIBULIN MESYLATE | 4 | 1 |
| IFOSFAMIDE | 4 | 1 |
| IMATINIB | 4 | 1 |
| IXABEPILONE | 4 | 1 |
| MIRVETUXIMAB SORAVTANSINE | 4 | 1 |
| PAZOPANIB HYDROCHLORIDE | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| INIPARIB | 3 | 1 |
| SARACATINIB | 3 | 1 |
| SPARTALIZUMAB | 3 | 1 |
| CHEMBL3109278 | 0 | 1 |
| CHEMBL4438584 | 0 | 1 |